CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Fundamental Analysis

NASDAQ:CTNM • US21217B1008

15.34 USD
-0.44 (-2.79%)
At close: Feb 27, 2026
15.34 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

CTNM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. CTNM has a great financial health rating, but its profitability evaluates not so good. CTNM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CTNM had negative earnings in the past year.
  • CTNM had a negative operating cash flow in the past year.
CTNM Yearly Net Income VS EBIT VS OCF VS FCFCTNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • The Return On Assets of CTNM (-31.09%) is comparable to the rest of the industry.
  • With a decent Return On Equity value of -33.18%, CTNM is doing good in the industry, outperforming 63.21% of the companies in the same industry.
Industry RankSector Rank
ROA -31.09%
ROE -33.18%
ROIC N/A
ROA(3y)-16.78%
ROA(5y)N/A
ROE(3y)-21.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTNM Yearly ROA, ROE, ROICCTNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CTNM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTNM Yearly Profit, Operating, Gross MarginsCTNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • CTNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CTNM has been increased compared to 1 year ago.
  • There is no outstanding debt for CTNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CTNM Yearly Shares OutstandingCTNM Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
CTNM Yearly Total Debt VS Total AssetsCTNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 28.02 indicates that CTNM is not in any danger for bankruptcy at the moment.
  • CTNM has a Altman-Z score of 28.02. This is amongst the best in the industry. CTNM outperforms 91.19% of its industry peers.
  • CTNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 28.02
ROIC/WACCN/A
WACC9.17%
CTNM Yearly LT Debt VS Equity VS FCFCTNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 24.51 indicates that CTNM has no problem at all paying its short term obligations.
  • CTNM's Current ratio of 24.51 is amongst the best of the industry. CTNM outperforms 93.78% of its industry peers.
  • CTNM has a Quick Ratio of 24.51. This indicates that CTNM is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of CTNM (24.51) is better than 94.30% of its industry peers.
Industry RankSector Rank
Current Ratio 24.51
Quick Ratio 24.51
CTNM Yearly Current Assets VS Current LiabilitesCTNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • CTNM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -341.52%.
  • Looking at the last year, CTNM shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-341.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CTNM will show a small growth in Earnings Per Share. The EPS will grow by 7.22% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y56.31%
EPS Next 2Y23.21%
EPS Next 3Y15.09%
EPS Next 5Y7.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTNM Yearly Revenue VS EstimatesCTNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2027 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
CTNM Yearly EPS VS EstimatesCTNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CTNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTNM Price Earnings VS Forward Price EarningsCTNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTNM Per share dataCTNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CTNM's earnings are expected to grow with 15.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.21%
EPS Next 3Y15.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CTNM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CONTINEUM THERAPEUTICS INC-A

NASDAQ:CTNM (2/27/2026, 8:00:02 PM)

After market: 15.34 0 (0%)

15.34

-0.44 (-2.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30
Earnings (Next)03-05
Inst Owners56.01%
Inst Owner Change66.32%
Ins Owners1.48%
Ins Owner Change-1.49%
Market Cap560.37M
Revenue(TTM)N/A
Net Income(TTM)-56.86M
Analysts86.15
Price Target20.74 (35.2%)
Short Float %8.83%
Short Ratio9.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.86%
Min EPS beat(2)-38.15%
Max EPS beat(2)-7.58%
EPS beat(4)1
Avg EPS beat(4)-17.41%
Min EPS beat(4)-38.15%
Max EPS beat(4)4.35%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)5.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.27
P/tB 3.27
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-2.36
Fwd EYN/A
FCF(TTM)-1.28
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0
BVpS4.69
TBVpS4.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.09%
ROE -33.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.78%
ROA(5y)N/A
ROE(3y)-21.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 115.31%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.51
Quick Ratio 24.51
Altman-Z 28.02
F-Score2
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)149.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-341.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y56.31%
EPS Next 2Y23.21%
EPS Next 3Y15.09%
EPS Next 5Y7.22%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-416.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.7%
EBIT Next 3Y-41.47%
EBIT Next 5YN/A
FCF growth 1Y-276.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-269.75%
OCF growth 3YN/A
OCF growth 5YN/A

CONTINEUM THERAPEUTICS INC-A / CTNM FAQ

What is the ChartMill fundamental rating of CONTINEUM THERAPEUTICS INC-A (CTNM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTNM.


What is the valuation status for CTNM stock?

ChartMill assigns a valuation rating of 0 / 10 to CONTINEUM THERAPEUTICS INC-A (CTNM). This can be considered as Overvalued.


Can you provide the profitability details for CONTINEUM THERAPEUTICS INC-A?

CONTINEUM THERAPEUTICS INC-A (CTNM) has a profitability rating of 1 / 10.


Can you provide the financial health for CTNM stock?

The financial health rating of CONTINEUM THERAPEUTICS INC-A (CTNM) is 8 / 10.